Fulgent Genetics, Inc. (FLGT)
NASDAQ: FLGT · Real-Time Price · USD
20.16
+0.52 (2.65%)
Jul 30, 2026, 3:51 PM EDT - Market open
Fulgent Genetics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 23.4 | 50.19 | 55.14 | 97.47 | 79.51 | 164.89 |
Short-Term Investments | 252.9 | 285.88 | 202.96 | 326.68 | 446.73 | 285.61 |
Cash & Short-Term Investments | 276.3 | 336.08 | 258.11 | 424.15 | 526.24 | 450.5 |
Cash Growth | -13.74% | 30.21% | -39.15% | -19.40% | 16.81% | 50.48% |
Accounts Receivable | 69.28 | 84.76 | 69.02 | 51.13 | 52.75 | 138.91 |
Other Current Assets | 133.46 | 129.65 | 26.44 | 32.56 | 48.89 | 22.55 |
Total Current Assets | 479.04 | 550.49 | 353.57 | 507.85 | 627.87 | 611.96 |
Net Property, Plant & Equipment | 116.34 | 112.55 | 105.55 | 83.46 | 81.35 | 62.29 |
Other Intangible Assets | 153.99 | 133.28 | 134.98 | 143.05 | 150.64 | 35.91 |
Goodwill | 53.73 | 25.08 | 22.06 | 22.06 | 143.03 | 50.9 |
Long-Term Investments | 328.29 | 369.27 | 570.35 | 444.01 | 339.03 | 507.01 |
Other Long-Term Assets | 24.98 | 22.86 | 33.46 | 34.9 | 44.12 | 10.65 |
Total Assets | 1,156 | 1,214 | 1,220 | 1,235 | 1,386 | 1,279 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 21.13 | 18.65 | 18.36 | 15.36 | 23.09 | 20.49 |
Accrued Expenses | 34.9 | 34.06 | 24.28 | 30.74 | 24.98 | 18.48 |
Current Portion of Long-Term Debt | 0.48 | 0.48 | 0.41 | 1.18 | 5.64 | 6.15 |
Unearned Revenue | 33.63 | 31.78 | 29.84 | 25.57 | 14.09 | 34.38 |
Other Current Liabilities | - | - | - | 0.16 | 20.3 | 25.82 |
Total Current Liabilities | 90.13 | 84.97 | 72.9 | 73.02 | 88.11 | 105.31 |
Other Long-Term Liabilities | 22.08 | 21.84 | 17.91 | 29.02 | 28.07 | 7.53 |
Total Long-Term Liabilities | 22.08 | 21.84 | 17.91 | 29.02 | 28.07 | 7.53 |
Total Liabilities | 112.22 | 106.81 | 90.81 | 102.04 | 116.18 | 112.84 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-in Capital | 540.14 | 574.52 | 543.13 | 501.72 | 486.59 | 501.91 |
Accumulated Other Comprehensive Income | 4.54 | 7.51 | -0.37 | 1.21 | -20.9 | -0.76 |
Retained Earnings | 505.13 | 529.95 | 590.47 | 633.18 | 801 | 657.6 |
Total Common Shareholders' Equity | 1,050 | 1,112 | 1,133 | 1,136 | 1,267 | 1,159 |
Minority Interest | -5.66 | -5.27 | -4.07 | -2.82 | 3.19 | 7.13 |
Shareholders' Equity | 1,044 | 1,107 | 1,129 | 1,133 | 1,270 | 1,166 |
Total Liabilities & Equity | 1,156 | 1,214 | 1,220 | 1,235 | 1,386 | 1,279 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 0.48 | 0.48 | 0.41 | 1.18 | 5.64 | 6.15 |
Net Cash (Debt) | 275.82 | 335.6 | 257.69 | 422.97 | 520.6 | 444.35 |
Net Cash Growth | -13.76% | 30.23% | -39.07% | -18.75% | 17.16% | 48.43% |
Net Cash Per Share | 8.96 | 10.90 | 8.52 | 14.20 | 16.81 | 14.35 |
Book Value | 1,050 | 1,112 | 1,133 | 1,136 | 1,267 | 1,159 |
Book Value Per Share | 34.10 | 36.13 | 37.48 | 38.14 | 40.91 | 37.41 |
Tangible Book Value | 842.09 | 953.63 | 976.2 | 970.99 | 973.02 | 1,072 |
Tangible Book Value Per Share | 27.35 | 30.99 | 32.29 | 32.60 | 31.42 | 34.61 |